|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Venook AP, Niedzwiecki D, Lenz HJ,
Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH,
Atkins JN, et al: Effect of first-line chemotherapy combined with
cetuximab or bevacizumab on overall survival in patients with KRAS
wild-type advanced or metastatic colorectal cancer: A randomized
clinical trial. Jama. 317:2392–2401. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim SY and Kim TW: Current challenges in
the implementation of precision oncology for the management of
metastatic colorectal cancer. ESMO Open. 5:e0006342020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhao B, Wang L, Qiu H, Zhang M, Sun L,
Peng P, Yu Q and Yuan X: Mechanisms of resistance to anti-EGFR
therapy in colorectal cancer. Oncotarget. 8:3980–4000. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Martinelli E, Ciardiello D, Martini G,
Troiani T, Cardone C, Vitiello PP, Normanno N, Rachiglio AM,
Maiello E, Latiano T, et al: Implementing anti-epidermal growth
factor receptor (EGFR) therapy in metastatic colorectal cancer:
Challenges and future perspectives. Ann Oncol. 31:30–40. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li QH, Wang YZ, Tu J, Liu CW, Yuan YJ, Lin
R, He WL, Cai SR, He YL and Ye JN: Anti-EGFR therapy in metastatic
colorectal cancer: Mechanisms and potential regimens of drug
resistance. Gastroenterol Rep (Oxf). 8:179–191. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ratner N and Miller SJ: A RASopathy gene
commonly mutated in cancer: The neurofibromatosis type 1 tumour
suppressor. Nat Rev Cancer. 15:290–301. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
de Bruin EC, Cowell C, Warne PH, Jiang M,
Saunders RE, Melnick MA, Gettinger S, Walther Z, Wurtz A, Heynen
GJ, et al: Reduced NF1 expression confers resistance to EGFR
inhibition in lung cancer. Cancer Discov. 4:606–619. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Woolston A, Khan K, Spain G, Barber LJ,
Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M, Patil Y,
Newey A, et al: Genomic and transcriptomic determinants of therapy
resistance and immune landscape evolution during Anti-EGFR
treatment in colorectal cancer. Cancer Cell. 36:35–50.e39. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cancer Genome Atlas Research Network, .
Comprehensive genomic characterization of squamous cell lung
cancers. Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cancer Genome Atlas Network, .
Comprehensive molecular portraits of human breast tumours. Nature.
490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Krauthammer M, Kong Y, Bacchiocchi A,
Evans P, Pornputtapong N, Wu C, McCusker JP, Ma S, Cheng E, Straub
R, et al: Exome sequencing identifies recurrent mutations in NF1
and RASopathy genes in sun-exposed melanomas. Nat Genet.
47:996–1002. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yap YS, McPherson JR, Ong CK, Rozen SG,
Teh BT, Lee AS and Callen DF: The NF1 gene revisited -from bench to
bedside. Oncotarget. 5:5873–5892. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Whittaker SR, Theurillat JP, Van Allen E,
Wagle N, Hsiao J, Cowley GS, Schadendorf D, Root DE and Garraway
LA: A genome-scale RNA interference screen implicates NF1 loss in
resistance to RAF inhibition. Cancer Discov. 3:350–362. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mendes-Pereira AM, Sims D, Dexter T,
Fenwick K, Assiotis I, Kozarewa I, Mitsopoulos C, Hakas J, Zvelebil
M, Lord CJ and Ashworth A: Genome-wide functional screen identifies
a compendium of genes affecting sensitivity to tamoxifen. Proc Natl
Acad Sci USA. 109:2730–2735. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hölzel M, Huang S, Koster J, Ora I,
Lakeman A, Caron H, Nijkamp W, Xie J, Callens T, Asgharzadeh S, et
al: NF1 is a tumor suppressor in neuroblastoma that determines
retinoic acid response and disease outcome. Cell. 142:218–229.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Berg KCG, Eide PW, Eilertsen IA,
Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA,
Eknæs M, Lind GE, et al: Multi-omics of 34 colorectal cancer cell
lines-a resource for biomedical studies. Mol Cancer. 16:1162017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Park HJ, Lee SJ, Sohn YB, Jin HS, Han JH,
Kim YB, Yim H and Jeong SY: NF1 deficiency causes Bcl-xL
upregulation in Schwann cells derived from neurofibromatosis type
1-associated malignant peripheral nerve sheath tumors. Int J Oncol.
42:657–666. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schneider CA, Rasband WS and Eliceiri KW:
NIH image to imageJ: 25 years of image analysis. Nat Methods.
9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schuierer S, Carbone W, Knehr J, Petitjean
V, Fernandez A, Sultan M and Roma G: A comprehensive assessment of
RNA-seq protocols for degraded and low-quantity samples. BMC
Genomics. 18:1–13. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Andrews S: FastQC: A quality control tool
for high through-put sequence data. Babraham Institute.
(Cambridge). 2010.http://www.bioinformatics.babraham.ac.uk/projects/fastqc/November
11–2019
|
|
23
|
Krueger F: Trim galore: A wrapper tool
around Cutadapt and FastQC to consistently apply quality and
adapter trimming to FastQ files with some extra functionality for
MspI-digested RRBS-type (Reduced Representation Bisufite-Seq)
libraries. Babraham Institute. (Cambridge). 2015.https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/November
11–2019
|
|
24
|
Dobin A, Davis CA, Schlesinger F, Drenkow
J, Zaleski C, Jha S, Batut P, Chaisson M and Gingeras TR: STAR:
Ultrafast universal RNA-seq aligner. Bioinformatics. 29:15–21.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li B and Dewey CN: RSEM: Accurate
transcript quantification from RNA-Seq data with or without a
reference genome. BMC Bioinformatics. 12:3232011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Love MI, Huber W and Anders S: Moderated
estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kanehisa M, Sato Y, Kawashima M, Furumichi
M and Tanabe M: KEGG as a reference resource for gene and protein
annotation. Nucleic Acids Res. 44:D457–D462. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim JE, Chun SM, Hong YS, Kim KP, Kim SY,
Kim J, Sung CO, Cho EJ, Kim TW and Jang SJ: Mutation burden and I
index for detection of microsatellite instability in colorectal
cancer by targeted next-generation sequencing. J Mol Diagn.
21:241–250. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Philpott C, Tovell H, Frayling IM, Cooper
DN and Upadhyaya M: The NF1 somatic mutational landscape in
sporadic human cancers. Hum Genomics. 11:132017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Redig AJ, Capelletti M, Dahlberg SE, Sholl
LM, Mach S, Fontes C, Shi Y, Chalasani P and Jänne PA: Clinical and
molecular characteristics of NF1-mutant lung cancer. Clin Cancer
Res. 22:3148–3156. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hayashi T, Desmeules P, Smith RS, Drilon
A, Somwar R and Ladanyi M: RASA1 and NF1 are preferentially
co-mutated and define a distinct genetic subset of
smoking-associated non-small cell lung carcinomas sensitive to MEK
inhibition. Clin Cancer Res. 24:1436–1447. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dischinger PS, Tovar EA, Essenburg CJ,
Madaj ZB, Gardner EE, Callaghan ME, Turner AN, Challa AK, Kempston
T, Eagleson B, et al: NF1 deficiency correlates with estrogen
receptor signaling and diminished survival in breast cancer. NPJ
Breast Cancer. 4:292018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pearson A, Proszek P, Pascual J, Fribbens
C, Shamsher MK, Kingston B, O'Leary B, Herrera-Abreu MT, Cutts RJ,
Garcia-Murillas I, et al: Inactivating NF1 mutations are
enriched in advanced breast cancer and contribute to endocrine
therapy resistance. Clin Cancer Res. 26:608–622. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mei Z, Shao YW, Lin P, Cai X, Wang B, Ding
Y, Ma X, Wu X, Xia Y, Zhu D, et al: SMAD4 and NF1 mutations as
potential biomarkers for poor prognosis to cetuximab-based therapy
in Chinese metastatic colorectal cancer patients. BMC Cancer.
18:4792018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cancer Genome Atlas Network, .
Comprehensive molecular characterization of human colon and rectal
cancer. Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Meng M, Zhong K, Jiang T, Liu Z, Kwan HY
and Su T: The current understanding on the impact of KRAS on
colorectal cancer. Biomed Pharmacother. 140:1117172021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
McFall T, Diedrich JK, Mengistu M,
Littlechild SL, Paskvan KV, Sisk-Hackworth L, Moresco JJ, Shaw AS
and Stites EC: A systems mechanism for KRAS mutant allele-specific
responses to targeted therapy. Sci Signal. 12:eaaw82882019.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Georgiou A, Stewart A, Cunningham D,
Banerji U and Whittaker SR: Inactivation of NF1 promotes resistance
to EGFR inhibition in KRAS/NRAS/BRAFV600 -wild-type
colorectal cancer. Mol Cancer Res. 18:835–846. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bray SM, Lee J, Kim ST, Hur JY, Ebert PJ,
Calley JN, Wulur IH, Gopalappa T, Wong SS, Qian HR, et al: Genomic
characterization of intrinsic and acquired resistance to cetuximab
in colorectal cancer patients. Sci Rep. 9:153652019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
AACR Project GENIE: Powering precision
medicine through an international consortium. Cancer Discov.
7:818–831. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kandoth C, McLellan MD, Vandin F, Ye K,
Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al:
Mutational landscape and significance across 12 major cancer types.
Nature. 502:333–339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Baeissa HM, Benstead-Hume G, Richardson CJ
and Pearl FM: Mutational patterns in oncogenes and tumour
suppressors. Biochem Soc Trans. 44:925–931. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gutmann DH, Wu YL, Hedrick NM, Zhu Y, Guha
A and Parada LF: Heterozygosity for the neurofibromatosis 1 (NF1)
tumor suppressor results in abnormalities in cell attachment,
spreading and motility in astrocytes. Hum Mol Genet. 10:3009–3016.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Brosseau JP, Liao CP, Wang Y, Ramani V,
Vandergriff T, Lee M, Patel A and Ariizumi K: NF1 heterozygosity
fosters de novo tumorigenesis but impairs malignant transformation.
Nat Commun. 9:50142018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Guo XE, Ngo B, Modrek AS and Lee WH:
Targeting tumor suppressor networks for cancer therapeutics. Curr
Drug Targets. 15:2–16. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bai RY, Esposito D, Tam AJ, McCormick F,
Riggins GJ, Clapp DW and Staedtke V: Feasibility of using NF1-GRD
and AAV for gene replacement therapy in NF1-associated tumors. Gene
Ther. 26:277–286. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kong N, Tao W, Ling X, Wang J, Xiao Y, Shi
S, Ji X, Shajii A, Gan ST, Kim NY, et al: Synthetic mRNA
nanoparticle-mediated restoration of p53 tumor suppressor
sensitizes p53-deficient cancers to mTOR inhibition. Sci Transl
Med. 11:eaaw15652019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
El Sharkawi FZ, Ewais SM, Fahmy RH and
Rashed LA: PTEN and TRAIL genes loaded zein nanoparticles as
potential therapy for hepatocellular carcinoma. J Drug Target.
25:513–522. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Groelz D, Sobin L, Branton P, Compton C,
Wyrich R and Rainen L: Non-formalin fixative versus formalin-fixed
tissue: A comparison of histology and RNA quality. Exp Mol Pathol.
94:188–194. 2013. View Article : Google Scholar : PubMed/NCBI
|
